Eris Lifesciences Limited Bombay S.E.

ERIS

INE406M01024

Pharmaceuticals

Delayed Bombay S.E. Other stock markets 11:00:53 16/07/2024 BST			5-day change	1st Jan Change
1,014 ^INR	-0.47%		-1.75%	+11.38%

06-12	Eris Lifesciences Completes Acquisition of 19% Stake in Swiss Parenterals	MT
06-11	Eris Lifesciences Limited completed the acquisition of additional 19% stake in Swiss Parenterals Limited from Amit Indubhushan Bakshi, Inderjeet Singh Negi, Kaushal Kamlesh Shah and Rajendra Rambhai Patel.	CI

Eris Lifesciences Private Limited Reports Earnings Results for the Third Quarter Ended December 31, 2018

January 29, 2019 at 10:35 am

Eris Lifesciences Private Limited announced earnings results for the third quarter ended December 31, 2018.

Latest news about Eris Lifesciences Limited

Eris Lifesciences Completes Acquisition of 19% Stake in Swiss Parenterals	06-12	MT
Eris Lifesciences Limited completed the acquisition of additional 19% stake in Swiss Parenterals Limited from Amit Indubhushan Bakshi, Inderjeet Singh Negi, Kaushal Kamlesh Shah and Rajendra Rambhai Patel.	06-10	CI
Eris Lifesciences Posts Gains in Fiscal Q4 Consolidated Net Profit	05-22	MT
Eris Lifesciences Gets Board Nod to Raise Up to INR12.50 Billion Via Bond Sale	05-21	MT
Transcript : Eris Lifesciences Limited, Q4 2024 Earnings Call, May 21, 2024	05-21
Eris Lifesciences Completes Acquisition of Biocon Biologics' India Formulation Business	04-03	MT
Eris Lifesciences to Acquire India Formulation Business of Biocon Biologics for INR12.42 Billion	03-15	MT
Transcript : Eris Lifesciences Limited - Shareholder/Analyst Call	03-14
Eris to Acquire Additional Stake in Swiss Parenterals, Take Over Branded Formulations Business of Biocon Biologics	03-14	MT
India's Biocon to sell branded formulations business to Eris Lifesciences for $150 million	03-14	RE
Eris Lifesciences Limited agreed to acquire additional 19% stake in Swiss Parenterals Limited from Amit Indubhushan Bakshi, Inderjeet Singh Negi, Kaushal Kamlesh Shah and Rajendra Rambhai Patel for INR 2.4 billion.	03-13	CI
Eris Lifesciences Limited agreed to acquire Biocon Biologics India Branded Formulations business for INR 12.42 billion.	03-13	CI
Eris Lifesciences Completes Purchase of 51% Stake in Swiss Parenterals	02-16	MT
Eris Lifesciences Limited completed the acquisition of 51% stake in Swiss Parenterals Limited.	02-14	CI
Eris Lifesciences Limited Provides Earnings Guidance for the Fiscal 2025 and Fiscal 2026	02-13	CI
Transcript : Eris Lifesciences Limited, Q3 2024 Earnings Call, Feb 13, 2024	02-13
Eris Lifesciences Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	02-13	CI
Eris Lifesciences Limited agreed to acquire 51% stake in Swiss Parenterals Limited INR 6.4 billion.	02-12	CI
India's Biocon posts profit on biosimilar boost, divestment gains; CFO resigns	02-08	RE
Eris Lifesciences Limited completed the acquisition of Dermatology and Nephrology branded formulations business units of Biocon Biologics	11-09	CI
Indian shares set to open higher tracking Asian peers	11-09	RE
Eris Lifesciences Limited Reaffirms Earnings Guidance for the Full Year of Fiscal 2024	11-08	CI
Transcript : Eris Lifesciences Limited, Q2 2024 Earnings Call, Nov 08, 2023	11-08
Eris Lifesciences Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	11-08	CI
Eris Lifesciences Limited entered into a definitive agreement to acquire Dermatology and Nephrology branded formulations business units of Biocon Biologics for INR 3.7 billion.	11-07	CI

Chart Eris Lifesciences Limited

Duration

Period

More charts

Eris Lifesciences Limited is an India-based company that is primarily engaged in the manufacturing and marketing of pharmaceutical products. The Companyâs manufacturing plant is located in Guwahati, Assam. Its therapeutic areas include oral diabetes care, cardiac care, pain/analgesics, gynecology, gastrointestinal, central nervous system (CNS), and vitamins, minerals, and nutrients (VMN). The Company's brands include Advog 0.2, Atorsave Gold 10, Baga NT 100, Calshine 60K Tablet, Carpela, Cilentra Plus 5, Cognix, D1000cal, Enoxsave 60, Glimisave M 4 forte, Levroxa 1000, Mac Rabonik Plus, Glimisave, Eritel, Renerve, Tendia, Olmin, Rabonik, Tayo, Cyblex, Lnbloc, Remylin, Zomelis, Crevast, Atorsave, Ginkocer and Metital. The Companyâs wholly owned subsidiaries include Kinedex Healthcare Private Limited, Aprica Healthcare Limited, and Eris Healthcare Private Limited.

Sector

Pharmaceuticals

Calendar

25/07/2024 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Eris Lifesciences Limited

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1,015 INR

Average target price

1,111 INR

Spread / Average Target

+9.37%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ELI LILLY AND COMPANY	+61.53%	848B
NOVO NORDISK A/S	+38.95%	627B
JOHNSON & JOHNSON	-3.66%	363B
MERCK & CO., INC.	+15.06%	318B
ABBVIE INC.	+9.18%	299B
ROCHE HOLDING AG	+5.89%	234B
NOVARTIS AG	+16.53%	225B
AMGEN INC.	+15.67%	179B
PFIZER, INC.	+2.47%	167B

Other Pharmaceuticals

Eris Lifesciences Limited Bombay S.E.

Equities

ERIS

INE406M01024

Pharmaceuticals

Eris Lifesciences Private Limited Reports Earnings Results for the Third Quarter Ended December 31, 2018

Latest news about Eris Lifesciences Limited

Chart Eris Lifesciences Limited

Company Profile

Income Statement Evolution

Ratings for Eris Lifesciences Limited

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals